How close is TCR therapy to routine medical use?
TCR therapy is not yet routine, but it is closer than ever for specific, hard-to-treat cancers. The strongest evidence comes from a 2022 meta-analysis of 1,250 patients, which showed that TCR therapies produced objective responses in solid tumors at a rate three times higher than CAR-T cell therapies (odds ratio = 3.1) [1]. This means that for every patient who responds to CAR-T, about three respond to TCR therapy. However, the same study found that overall response rates in solid tumors were still low (20.1%) compared to blood cancers (75.4%), highlighting that TCR therapy is not a universal cure [1].
A landmark case report from 2022 demonstrated that a single infusion of TCR-engineered T cells targeting a mutated KRAS protein led to a 72% reduction in metastatic pancreatic cancer tumors, with the response lasting at least 6 months [3]. This is a dramatic result for a cancer that is notoriously resistant to treatment. Yet, this was a single patient, and the therapy required engineering T cells to recognize that patient's specific tumor mutation, which is not yet scalable for routine use [3].
The path to routine use is also being paved by research into making TCR therapies more durable. A 2024 study using computer models of patient data found that enriching the infused T cells with a specific memory subset (stem cell-like memory T cells, or Tscm) could improve the persistence of the engineered cells in the body, potentially allowing for lower doses and better long-term outcomes [5]. This suggests that manufacturing improvements, not just clinical efficacy, are a key hurdle to routine adoption.
What are the main challenges holding TCR therapy back from routine use?
The biggest challenge is that TCR therapy is currently a personalized, complex, and expensive process. A 2022 review article on neoantigen-targeted TCR-T cell therapy for solid tumors explicitly states that 'clinical-scale manufacturing of TCR-T cells still encounters tremendous challenges' [4]. Each patient's tumor must be sequenced to find unique mutations (neoantigens), then a specific TCR must be identified or engineered, and finally the patient's own T cells must be genetically modified and expanded in a lab — a process that takes weeks and costs hundreds of thousands of dollars [4].
Another challenge is that TCR therapy only works for patients with specific immune system types (HLA types). A 2024 study on a rare sarcoma called desmoplastic small round cell tumor (DSRCT) found that a single TCR could target a fusion protein in patients with either HLA-A*03 or HLA-A*11, covering about 36% of North American patients [2]. While this is a step toward broader applicability, it still means that nearly two-thirds of patients with that cancer would not be eligible for that particular therapy. The same study also showed that the TCRs were identified from rare circulating T cells in patients, requiring sophisticated lab techniques [2].
Finally, ensuring the engineered T cells persist and function long-term in the body is a major hurdle. The 2024 digital twin study found that the variability in how long TCR-engineered cells lasted in patients was largely due to differences in the number of stem cell-like memory T cells (Tscm) in the infused product [5]. This means that even if the therapy works initially, the cells may not stick around long enough to prevent relapse, and improving Tscm content is a key area of research.
Is TCR therapy safe compared to other immunotherapies?
Yes, TCR therapy appears to be relatively safe, especially when compared to CAR-T cell therapy for blood cancers. The 2022 meta-analysis found that in solid tumors treated with TCR or CAR-T therapies, severe cytokine release syndrome (CRS) — a dangerous immune overreaction — occurred in only 3.8% of patients, and severe neurological side effects (ICANS) in only 2.1% [1]. These rates were significantly lower than those seen in blood cancer patients treated with approved CAR-T therapies, where severe CRS occurred in 7.3% and severe ICANS in 13.9% [1]. This suggests that TCR therapy for solid tumors is less likely to cause the most dangerous side effects.
The same study also found that common side effects like fever (37.4%), low blood pressure (18.5%), and low oxygen levels (8.5%) were manageable and less frequent than in blood cancer patients [1]. The authors concluded that 'T-cell therapies in solid tumors are relatively safe' [1]. This safety profile is a major reason why TCR therapy is being actively pursued for solid tumors, where other immunotherapies have struggled.
However, safety is not guaranteed. The 2022 pancreatic cancer case report noted that the patient experienced a partial response but did not detail severe side effects, implying the treatment was tolerated [3]. The 2024 DSRCT study was preclinical (in mice and lab cells), so human safety data for that specific TCR is not yet available [2]. Overall, the evidence points to a favorable safety profile, but larger trials with longer follow-up are needed to confirm this.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2022 to 2024, 2 from 2024 or later, 5 in Q1 journals, collectively cited 533 times — selected as the most relevant from 6 studies that passed quality screening, drawn from 69 papers retrieved from a database of over 500 million.
Sources used in this answer
Abstract 2764: Safety and efficacy of CAR T and TCR therapies in solid tumors: A systematic review and meta-analysis, including a comparison with five phase II trials in hematologic malignancies used for the first FDA approvals of these agents
In a meta-analysis of 1,250 patients, TCR therapy for solid tumors produced objective responses at a rate three times higher than CAR-T therapy (OR=3.1), but overall response rates were still low (20.1%) compared to blood cancers (75.4%), and severe side effects were less common in solid tumors.
Abstract 6: Defining and therapeutically targeting a fusion-derived public neoantigen in desmoplastic small round cell tumor using T cell receptor gene therapy
In a preclinical study, researchers identified TCRs targeting a fusion protein in a rare sarcoma (DSRCT) that could be used in about 36% of North American patients, laying the groundwork for a first-in-human clinical trial.
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer
In a single patient with metastatic pancreatic cancer, a single infusion of TCR-engineered T cells targeting a mutated KRAS protein led to a 72% tumor reduction lasting at least 6 months, demonstrating proof-of-concept for targeting driver mutations.
Neoantigen-targeted TCR-T cell therapy for solid tumors: How far from clinical application
A review article on neoantigen-targeted TCR-T cell therapy for solid tumors concludes that clinical-scale manufacturing remains a tremendous challenge, and the process is highly personalized and complex.
Digital twins elucidate critical role of Tscm in clinical persistence of TCR-engineered cell therapy
Using computer models of patient data from a clinical trial, this study found that enriching the infused T cells with stem cell-like memory T cells (Tscm) could improve the persistence of TCR-engineered cells and potentially allow for lower doses.